Kornimate/medical-research-clean huggingface dataset:
effect of cardiac computed tomography angiography on the blood reactive oxygen species level

Conditions: Radiation Injury

Summary: the clinically widely used x-ray computed tomography examination has a low-grade radiation effect and recently has attracted much attention concerning the possible adverse effects of radiation on human body \[ref. 1-5\]. the radiation is harmful to human tissues and cells mainly because it can interact with water (which makes up to 80% of cells) to generate reactive oxygen species (ros), especially the formation of hydroxyl radicals. so far as we can reach, there is no report concerning the relation between x-ray computed tomography examination and the blood ros level. therefore, we wish to conduct this study to clarify if the cardiac computed tomography angiography (cardiac cta) may induce a higher level of ros in the peripheral blood. study subjects will be opd patients who are arranged for cardiac cta examination because of suspect coronary artery disease (cad). in total, twenty cases will be enrolled for the study. the formal consent will be delivered and explained to the patients and families after the arrangement of cardiac cta. it then will be retrieved just before the performance of cardiac cta. for each enrolled case, peripheral blood will be sampled three times (once before and twice after the performance of cardiac cta). totally 60 blood samples will be collected from 20 study subjects within 3 months (january 1 \~ march 31, 2009). ros level in the collected blood samples will be then measured, compared, and analyzed.


Eligibility criteria:
inclusion criteria: * subjects who are arranged for cardiac cta examination because of suspect coronary artery disease. exclusion criteria: * none

Keywords: radiation injury computed tomography reactive oxygen species free radicals
prevalence of monoclonal gammopathy of undetermined significance (mgus) / multiple myeloma (mm) among unique populations of black people

Conditions: Monoclonal Gammopathy of Undetermined Significance

Summary: this study is being done to screen for monoclonal gammopathies in people of east african descent. monoclonal gammopathy is a condition where abnormal proteins are found in the blood, most commonly called monoclonal gammopathy of undetermined significance or mgus. there is little information on the presence of this condition in people of east african descent. this study is being done to determine how this condition affects this population in order to better treat and/or prevent this condition in the future.

primary objective: i. to determine the prevalence of monoclonal gammopathies (mgus, smoldering and multiple myeloma) in people of east african descent in minnesota. outline: this is an observational study. participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. participants who test positive for mgus are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.

Eligibility criteria:
inclusion criteria: * adults ≥ 40 years * self-reported east african ancestry (including individuals of mixed east african descent) * willing and able to review, understand, and provide consent before starting any study-specific procedures exclusion criteria: * pregnant women
comparison between electronic and traditional chest drainage systems

Conditions: Lung Cancer

Summary: this study is designed to compare the electronic chest drainage system (drentech palm evo) with the traditional system, both already in use in the clinical practice, in a cohort of patients who received thoracoscopic lobectomy. this study is not evaluating safety or efficacy of these systems. this study's primary aim is to determine if the use of a digital chest system compared with a traditional system reduce the duration of chest drainage and length of hospital stay. moreover, the investigators aim to quantify the variability of results regarding the subjective observer evaluation of active air leaks (through the traditional system) compared with the objective data registered by the digital system. finally the investigators want to evaluate whether it is possible through the digital device to distinguish an active air leak from a pleural space effect by the evaluation of intrapleural differential pressure and to identify potential predictors of prolonged air leaks.


Eligibility criteria:
inclusion criteria: * able and willing to read, understand and provide written informed consent * patients undergoing thoracoscopic lobectomy * age 18 - 80 years * gender: both * estimated life expectancy of at least 6 months. * tumour considered potentially resectable by r0 surgery * adequate respiratory function for surgery. * must have signed and dated an informed consent form (icf), before performance of any study-specific procedures or tests. subjects must be fully informed about their illness and the investigational nature of the study protocol. exclusion criteria: * patients requiring icu care with mechanical ventilation * patients needing reintervention during postoperative care * patients requiring a thoracotomy * tumour considered potentially resectable by incomplete surgical resection with microscopic residual disease (r1) or gross residual disease (r2). * evidence of extra-thoracic disease. * major thoracic surgical procedure before enrolment. * any other significant co-morbid condition that, in opinion of the investigator, would impair study participation or cooperation.

Keywords: chest tube, lung resection, air leakage
dpbrn retrospective cohort study of osteonecrosis of the jaw

Conditions: Osteonecrosis of the Jaw

Summary: the purpose of this study was to determine the prevalence of onj in the patient population of 2 large hmos and study the risk factors associated with the development of this condition.

the electronic database from kaiser permanente and healthparnters of minnesota were used to identify all onj cases that occured between 1994 and 2006 and then demographic, social and medical risk factors possibly associated with the disease were abstracted and analyzed.

Eligibility criteria:
inclusion criteria: * onj sufferers and control biphosphonate users older than 40, of any gender, race and ethnic origin

Keywords: onj
role of 18f-fdg pet/ct in the evaluation of cavernous sinus syndrome: a pilot study

Conditions: Cavernous Sinus Syndrome; Cavernous Sinus Meningioma; Cavernous Sinus Lesions

Summary: cavernous sinus syndrome (css) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders. even after modern advances, reaching the final etiological diagnosis remains a challenge in css. this study is planned to determine the role and incremental value of 18f-fdg pet/ct in characterising different cavernous sinus pathologies based on their metabolic activity and detecting extracranial involvement.


Eligibility criteria:
inclusion criteria: 1. patients with age greater than or equal to 18 years, 2. with newly diagnosed css, 3. lesion seen on mri in the cs, and 4. willing to give written informed consent. exclusion criteria: 1. pregnant and lactating patients 2. patients already being treated (including steroids)

Keywords: cavernous sinus syndromes ophthalmoplegia positron emission tomography computed tomography fluorodeoxyglucose f18 cavernous sinus
in vitro organoid drug sensitivity-guided treatment for advanced pancreatic neuroendocrine tumor

Conditions: Advanced Pancreatic Neuroendocrine Tumor

Summary: the purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic pancreatic neuroendocrine tumors. at the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response

twenty non-resectable locally advanced and metastatic pancreatic neuroendocrine tumor(p-net) patients who should receive palliative treatment will be enrolled in this study. baseline information of the enrolled patients including medical history, physical examination records and clinical examination records will be collected. tumor material of those patients will be obtained from pancreatic endoscopic biopsies or surgical resection. patient-derived organoids (pdos) will be established and cultured from p-net tumor specimens. pdos will then be treated with drugs of the chemotherapeutic and targeted therapeutic regimens for p-net. organoid size and growth will be monitored before and after the treatment, and dose-response curves will be generated. as for the assessment of clinical outcomes of patients, treatment responses will be assessed by biomedical imaging according to the response evaluation criteria in solid tumors (recist1.1). consistency between treatment responses in pdo models and clinical outcomes of patients will be assessed by correlation analysis.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 75 years old. 2. histologically or cytologically confirmed locally advanced/metastatic pancreatic neuroendocrine tumor 3. surgery was considered impossible or can not receive the radical purpose. 4. able to provide fresh tumor tissue specimens for organoid culture, including: tumor biopsy tissues, tumor surgical specimens, etcy. 5. eastern cooperative oncology group (ecog) performance status (ps) score of 0-2. 6. expected survival time≥ six months. 7. patient have been informed and consented, compliance and geographic proximity to ensure adequate follow-up exclusion criteria: 1. other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin. 2. history of severe cardiovascular events and myocardial infarction within twelve months before the study. 3. patients with psychiatric disorders or with psychotropic substance abuse and inability to abstain. 4. pregnant or breastfeeding women. 5. according to researcher's consideration, patients with other serious systemic diseases or other conditions that are not suitable for participation.

Keywords: p-net organoid chemotherapy target therapy
granulocyte transfusions in hematological patients with febrile neutropenia

Conditions: Neutropenia; Fever; Bacterial Infection; Fungal Infection; Fever of Unknown Origin; Hematological Neoplasms; Sepsis

Summary: the investigators retrospectively evaluated the efficacy of granulocyte transfusions as adjunctive treatment for severe infections in neutropenic fever unresponsive to antimicrobial therapy in hematological patients.


Eligibility criteria:
inclusion criteria: * fever; * presence of absolute neutrophil count \<0.5 x 10\^9/l * evidence of bacterial or fungal infections (including clinical signs of infection, positive cultures or biopsy, and radiological evidences) * unresponsiveness to appropriate antimicrobial therapy for at least 48 hours exclusion criteria: * none

Keywords: granulocyte transfusions
acupuncture for the sleep disorder of chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: the investigators will conduct acupuncture for participants with chronic fatigue syndrome(cfs). firstly the investigators aim to figure out the characteristic of sleep structure of cfs and the changes caused by acupuncture. secondly the investigators seek to investigate the characteristic of sleep-wake rhythm, slow wave sleep(sws)-rapid eye movement(rem)sleep rhythm, and rem sleep rhythm of cfs and the readjusting of acupuncture for it. thirdly the investigators want to know the efficacy of acupuncture for relieving the fatigue, reducing accompanying symptoms and for improving the life quality of cfs.

this trial is a randomized, placebo controlled clinical trial. 72 participants with cfs are randomly allocated to two different groups. treatment group is acupuncture, while the control group is sham acupuncture. the ratio of treatment group and control group is 2:1. both acupuncture and sham acupuncture group will receive 12 sessions of verum/sham acupuncture in 4 weeks. the result of this trial (available in 2011) will supply evidence on the efficacy of acupuncture for sleep disorder of cfs.

Eligibility criteria:
inclusion criteria: 1. participants who meet the diagnosis criteria of cfs; 2. clinically evaluated, exclude any disease that can explain the chronic fatigue; 3. the onset age of cfs is between 18 and 50 years old; 4. have not taken any hypnotic, melatonin, or antidepressants within 45 days; 5. willing to finish the whole observation period; 6. with written consent form signed by themselves. exclusion criteria: 1. chronic fatigue caused by diseases such as internal diseases(for example, pulmonary emphysema, rheumatoid arthritis, etc.), mental illness(for example, any type of dementia paranoids, depression, etc.), some diseases that just onset or evaluated (for example, sleep deprivation, untreated diabetes, etc.), some diseases that need recovery gradually(for example, restless legs syndrome, lactation, etc.), morbid obesity; 2. participants in other clinical research; 3. pregnant women, lactating women.

Keywords: chronic fatigue syndrome sleep disorder, adjustment acupuncture
study of interventional pulmonologic treatment of malignant central airway stricture

Conditions: Airway Obstruction

Summary: the purpose of this study is to evaluate the efficacy and safety of four interventional pulmonology techniques for the treatment of malignant central airway stricture. the four techniques are： * cryotherapy * argon plasma coagulation * stent * snare


Eligibility criteria:
inclusion criteria: * malignant neoplasm caused central airway stenosis * the degree of stenosis is above 50% * estimated survival duration is longer than 3 months * received no treatment one month before * can understand the statement informed consent * agree to enroll in the study exclusion criteria: * older than 70 years or younger than 18 years * not malignant neoplasm caused central airway stenosis * not central airway stenosis * existence of lumina collapse or twisting * severe arrhythmia, myocardial ischemia or hypertensive crisis * coagulation disorders * existence of severe organ disfunction * allergic to anesthesia drugs * refuse to participate the study

Keywords: neoplasm central airway obstruction
xenon combined with intraoperative thoracic epidural analgesia

Conditions: Colorectal Cancer

Summary: this is a monocentric study in 2 steps: a safety part to assess the feasibility of using xenon in association with a thoracic epidural analgesia (tea) with a sequential recruitment of 3, 6 or 9 patients according to predefined safety rules. the second part will randomly allocated patients (1:1) to receive tea+xenon or tea+desflurane. 28 patients will be enrolled and followed over 45 days.

the first step is divided into 3 parts. 9 patients will be sequentially enrolled (3 patients in each part). the patients will be followed during 45 days and the following rules will be used to assess the safety: first part: if no toxicity: initiation of the randomised part. if 1/3 toxicity: start of the second part. if 2 or 3/3 toxicity: end of the study. second part: same rules and possible start of the third part. third part: if no toxicity: initiation of the randomised part. if 1 or more toxicity: end of the study. the safety will be assessed after each part by an independent data safety monitoring board.

Eligibility criteria:
inclusion criteria: * older than 18 years old * planned surgery for oncologic colic and/or rectal surgery * asa score i or ii * indication of complementary thoracic epidural analgesia * agree to use an effective form of contraception * patients who can understand, read and write french language * covered by a medical insurance * patients who have dated/signed an inform consent exclusion criteria: * unstable angina within the 30 last days * myocardial infarction within 28 days prior to surgery * uncontrolled arterial high blood pressure * severe cardiac insufficiency * severe chronic obstructive pneumopathy * patient who requires fio2 \> 40% * patient already enrolled in a clinical study which may interfere with the present study * known hypersensitivity to one of the study drugs * history or familial history of malignant hyperthermia * documented high intracranial pressure * eclampsia or pre-eclampsia * pregnant or breastfeeding woman * liver injury (icterus) and/or unexplained fever and/or eosinophilia after halogen exposure * failure in epidural anesthesia installation * patient refusal * patient who can't be compliant to the present protocol

Keywords: anesthesia, epidural anagesia, colorectal surgery, xenon, hemodynamic change
mbarara acute heart failure registry

Conditions: Heartfailure

Summary: this is a prospective cohort to describe clinical characteristics, predictors of poor outcomes both during hospitalization and at home, functional status, and quality of life among patients aged 13 years or more, consecutively admitted with acute decompensated heart failure at mbarara regional referral hospital.

this is a prospective observational cohort study to collect comprehensive data of heartfailure patients during and after hospitalization for acute heart failure at mbarara regional referral hospital (mrrh), uganda. the investigators will collect sociodemographic, clinical, quality of life, functional status, and clinical cardiovascular disease measures during hospitalization and follow up for up to 1 year from the date of enrollment.

Eligibility criteria:
inclusion criteria: * patients admitted with a confirmed clinical diagnosis of acute heartfailure aged 13 years or above at mbarara regional referral hospital, uganda exclusion criteria: * body swelling from kidney disease, liver disease or malnutrition. * acute kidney disease with no previous history/documentation of heart disease. * history suggestive of chronic kidney disease with no previous history/documentation of heart disease. * history suggestive of chronic liver disease with no previous history/documentation of heart disease.

Keywords: heartfailure 1-year mortality heartfailure quality of life sub-saharan africa
non-invasive method for predicting the presence of gastroesophageal varices in patients with cirrhosis-a prospective, multicenter trial

Conditions: Gastroesophageal Varices; Decompensation Event

Summary: gastroesophageal varices are a complication of portal hypertension in cirrhosis.endoscopy is an unsatisfactory screening test.in this prospective clinical study,we will enroll patients with cirrhosis of various causes, all of whom undergo laboratory tests, elastography, and serum proteomic differential protein testing, including liver elastography (lsm) and spleen elastography (ssm). baveno vi or expanded bavenovi criteria are validated by comparing patients' lsm and plt. lsm, ssm, serum differential protein, platelet count, and egd data to evaluate the clinical value of ssm and differential proteins in excluding cirrhosis with varices. at the same time, a new predictive model of variceal varices will be established to evaluate the diagnostic value of ssm and differential protein for esophagogastric varices, and a non-invasive method for reliably predicting and evaluating cirrhosis with esophageal varices will be found. and each patient will be followed up every 6 months to 1 year, and the outcome event will be recorded.

gastroesophageal varices are a complication of portal hypertension in cirrhosis.endoscopy is invasive method as an unsatisfactory screening test.in this prospective clinical study, we will enroll patients with cirrhosis of various causes, all of patients whom undergo laboratory tests, elastography, and serum proteomic differential protein testing, including lsm and ssm. baveno vi or expanded bavenovi criteria are validated by comparing patients' lsm and plt. lsm,ssm, serum differential protein, platelet count, and egd data to evaluate the clinical value of ssm and differential proteins in excluding cirrhosis with varices. at the same time, based on ssm and serum differential protein, a new predictive model of variceal varices will be established to evaluate the diagnostic value of ssm and differential protein for esophagogastric varices, and a non-invasive method for reliably predicting and evaluating cirrhosis with esophageal varices will be found. and each patient will be followed up every 6 months to 1 year, and the outcome event will be recorded.

Eligibility criteria:
inclusion criteria: * 1. the age ranged from 18 to 80 years. 2. clinical or pathological diagnosis of cirrhosis; 3. electronic gastroscopy is planned; 4. to agree and sign the informed consent; exclusion criteria: * 1.orthotopic liver transplantation patients; 2. patients who have undergone transjugular intrahepatic portosystemic shunt (tips),or previous surgical shunt; 3. pregnant women; 4. neurological or psychiatric disorders;
study of mogamulizumab + medi4736 (durvalumab) and mogamulizumab + tremelimumab in subjects w/ advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: mogamulizumab in combination with medi4736 (durvalumab) and mogamulizumab in combination with tremelimumab in subjects with advanced solid tumors


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * locally advanced or metastatic solid tumors; * histologically or cytologically confirmed disease; * failed or were intolerant to at least one prior systemic treatment regimen with oral or iv medications and have no additional therapy options known to prolong survival with the exception of pd-1 or pd-l1 blockade therapy for subjects who will be enrolled in treatment arm a. subjects with non-small cell lung cancer must have received at least one platinum doublet regimen. subjects with known epidermal growth factor receptor tyrosine kinase inhibitor activating mutations or anaplastic lymphoma kinase rearrangement must have also exhausted approved targeted therapy options; * the subject has a tumor suitable for biopsy and is willing to undergo tumor biopsy, preferably of the primary tumor, within 28 days prior to cycle 1/visit day 1; exclusion criteria: * any concurrent chemotherapy, biologic, hormonal, radiation, or investigative therapy for cancer treatment within 21 days prior prior or within 6 weeks prior to cycle 1/visit day 1 for nitrosoureas or mitomycin c; * concurrent or prior use of immunosuppressive medication within 28 days; * active or prior documented autoimmune, or inflammatory bowel disease, or inflammatory bowel disease. or systemic treatment for psoriasis within the past 5 years.; * prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.

Keywords: advanced solid tumors solid tumors mogamulizumab medi4736 (durvalumab) tremelimumab poteligeo® kw-0761
testing the effects of an algorithm for neuropathic pain on patient and system outcomes

Conditions: Pain

Summary: the overall purpose of this project is to improve nurse skills regarding neuropathic pain (np) assessment, treatment and referral practices through implementation of an evidence-based algorithm and to improve selected patient outcomes as a result of algorithm use.

neuropathic pain (np) is defined as pain that arises from injury, disease or dysfunction of the central or peripheral nervous system. for the patient focused phase of the project np treatment will be guided via the peripheral neuropathy treatment algorithm. patients will receive algorithm-specific treatment for 12 weeks.

Eligibility criteria:
inclusion criteria: * cancer patients experiencing np from a variety of causes * np visual analogue scale (vas) score equal to or \> 4 with 12 week estimated duration * karnofsky performance status (kps) 60% or greater * age greater than 18 exclusion criteria: * patients undergoing anticancer or invasive pain procedures specifically intended to palliate np are ineligible